Allakos Inc

NASDAQ ALLK

Download Data

Allakos Inc Free Cash Flow Margin 3 year CAGR for the quarter ending December 31, 2023

Allakos Inc Free Cash Flow Margin 3 year CAGR is NA for the quarter ending December 31, 2023. The Free Cash Flow Margin measures the percentage of revenue that is converted into free cash flow. It indicates the company's ability to generate cash flow from its operations after accounting for capital expenditures. A higher margin suggests better cash flow generation and potential for reinvestment or distribution to shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
NASDAQ: ALLK

Allakos Inc

CEO Dr. Robert Alexander Ph.D.
IPO Date July 19, 2018
Location United States
Headquarters 975 Island Drive, Redwood City, CA, United States, 94065
Employees 131
Sector Healthcare
Industry Biotechnology
Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Similar companies

DAWN

Day One Biopharmaceuticals Inc

NA

NA

CRBU

Caribou Biosciences Inc

NA

NA

KURA

Kura Oncology Inc

NA

NA

NXTC

NextCure  Inc

NA

NA

GTHX

G1 Therapeutics Inc

NA

NA

HRTX

Heron Therapeuti

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email